Τίτλος:
Epigenetic inactivation of DNA repair in breast cancer
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The study of epigenetic mechanisms in cancer, such as DNA methylation and histone modifications, has revealed a plethora of events that contribute to cancer through stable changes in the expression of genes critical to transformation pathways. In this mini review we look at the different epigenetic modifications prevalent in this neoplastic phenotype, focusing on breast cancer. Most encouragingly, research in epigenetics has led to improved survival of patients with certain forms of lymphoma and leukemia through the use of drugs that alter DNA methylation and histone acetylation. Thus, we look at the clinical utility of targeting epigenetic pathways. In addition, we explore numerous other clinical applications of epigenetics, in areas such as cancer screening and early detection, prevention, classification for epidemiology and prognostic purposes, and predicting outcomes after standard therapy. © 2012 Elsevier Ireland Ltd.
Συγγραφείς:
Nowsheen, S.
Aziz, K.
Tran, P.T.
Gorgoulis, V.G.
Yang, E.S.
Georgakilas, A.G.
Εκδότης:
Elsevier Ireland Ltd
Λέξεις-κλειδιά:
4sc 202; azacitidine; DNA; entinostat; histone deacetylase inhibitor; hydralazine; microRNA; sulforaphane; tamoxifen; unclassified drug; valproate magnesium; valproic acid, breast cancer; breast carcinogenesis; cancer prognosis; cancer screening; cancer survival; cancer therapy; clinical trial (topic); DNA methylation; DNA repair; early diagnosis; epigenetics; gene expression; gene inactivation; histone acetylation; histone modification; human; leukemia; lung non small cell cancer; lymphoma; molecular interaction; myeloma; outcome assessment; ovary cancer; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phenotype; priority journal; prostate cancer; protein phosphorylation; short survey; solid tumor; triple negative breast cancer; uterine cervix cancer
DOI:
10.1016/j.canlet.2012.05.015
